24-05-2025
Analysts Are Bullish on These Healthcare Stocks: Verastem (VSTM), Kazia Therapeutics (KZIA)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Verastem (VSTM – Research Report) and Kazia Therapeutics (KZIA – Research Report) with bullish sentiments.
Confident Investing Starts Here:
Verastem (VSTM)
Mizuho Securities analyst Graig Suvannavejh reiterated a Buy rating on Verastem today and set a price target of $16.00. The company's shares closed last Friday at $8.09.
According to Suvannavejh has 0 stars on 0-5 stars ranking scale with an average return of -9.7% and a 37.0% success rate. Suvannavejh covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Neumora Therapeutics, Inc., and Amylyx Pharmaceuticals Inc.
Currently, the analyst consensus on Verastem is a Strong Buy with an average price target of $15.11, representing an 112.2% upside. In a report issued on May 8, Jefferies also maintained a Buy rating on the stock with a $19.00 price target.
Kazia Therapeutics (KZIA)
Maxim Group analyst Naz Rahman reiterated a Buy rating on Kazia Therapeutics yesterday and set a price target of $15.00. The company's shares closed last Friday at $3.52, close to its 52-week low of $0.88.
According to Rahman has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -21.6% and a 25.3% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Neurosense Therapeutics Ltd., Processa Pharmaceuticals, and Virpax Pharmaceuticals.
Kazia Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $3.00.
